Global Oral GLP-1 Agonists Market 2026 – 2035

It is estimated that the global oral GLP-1 agonists market will be valued at approximately USD 65.15 billion in 2025, rising to around USD 72.87 billion in 2026, and is expected to reach close to USD 206.83 billion by 2035, expanding at a CAGR of 12.25% during the forecast period from 2026 to 2035. The market is experiencing robust growth driven by the increasing burden of metabolic disorders, particularly diabetes and obesity, across both developed and emerging economies.

The shift toward patient-friendly therapies is encouraging the transition from injectable to oral formulations, improving treatment initiation and long-term compliance. Furthermore, continuous innovation in peptide stabilization and absorption technologies is enhancing drug performance. The growing inclusion of GLP-1 therapies in treatment guidelines, along with their demonstrated benefits in weight reduction and cardiometabolic health, is further supporting sustained market expansion.

Impact of US-Iran War on the Oral GLP-1 Agonists Market

The supply chain of raw materials, active pharmaceutical ingredients (APIs), and advanced excipients required to produce oral GLP-1 agonists (such as semaglutide and other small molecule candidates) has been impacted by a potential US-Iran war. Increasing crude oil prices and geopolitical instability in the Middle East would raise the costs of petrochemical-derived synthetic intermediates, specialty solvents, and purification resins used in peptide synthesis and formulation, thereby increasing production costs for oral GLP-1 agonists. Furthermore, disruptions to global logistics routes, particularly through the Strait of Hormuz, would delay the shipment of temperature-sensitive drug components and finished dosage forms between manufacturing hubs (e.g., China, India, and Europe) and key markets (e.g., the US, EU, and Japan), affecting inventory and pricing.   

Market Highlight

• The North America region holds a major share of 75.15% of the market.

• Semaglutide had the highest market share of oral GLP-1 agonists in 2025 by contributing nearly 52.8% of the sales with high clinical efficacy, primary use and oral formulations made available.

• Tirzepatide is expected to register the highest CAGR of approximately 12.5% during 2026-2035. This is due to its dual mechanism of action on the hormones involved in blood glucose control and achieving better metabolic results.

• The Type 2 Diabetes Mellitus segment accounted for the maximum share of over 55.5% by application in 2025 due to the high global disease burden resulting in rising demand for efficacious therapies for glycemic control.

• The obese / chronic weight management segment is anticipated to record the highest CAGR of around 12.6% during 2026 – 2035 by application, owing to growth in obesity rates and use of GLP-1 drugs for weight management.

• In Route of Administration, the Injectable/Parenteral segment led the market with approximately 49.5% market share in 2025 mainly attributed to its existing clinical application and robust product portfolio, while the Oral segment is expected to witness the fastest CAGR of 13% in the forecast period on account of increasing patient convenience and compliance.

Significant Growth Factors

The Market Trends of the Oral GLP-1 Agonists offer serious growth potential owing to a number of factors:

• Increasing Burden of Metabolic and Lifestyle Disorders: The prevalence of metabolic diseases such as type 2 diabetes and obesity has been increasing owing to urbanization, increased sedentarism and changing dietary patterns. Today, global incidence of these diseases is on the rise. Oral GLP-1 therapies are gaining prominence owing to perceived benefits of glucose control and weight reduction. Rising awareness about early intervention and preventive healthcare practices is also encouraging early treatment initiation. For the record, market data suggests an upward trajectory of diabetes cases over the next decade globally.

• Trend toward easier availability of patient-favorable treatment forms: The foremost trend of the market is the shift towards embracing more convenient treatment forms for better patient compliance. Oral GLP-1 agonist drug candidates overcome the limitation of injectable therapy by providing a more patient-friendly, painless and convenient alternative. This will especially appeal to the patient cohort that is in the initial stages of such therapy or is averse to starting injections. Better patient adherence will result in improved clinical outcomes and greater acceptance of the therapy. For example, owing to the need for better patient compliance, third-party payers have begun recommending oral therapy in an early stage of treatment.

• Ongoing Advancements in Oral Peptide formulation: As the pharmaceutical industry advances new delivery technologies, the potential for effective oral delivery of GLP-1 receptor agonists increases. Innovative formulation strategies, such as enteric protection and absorption enhancers, are leading to improved bioavailability and tolerated doses of medications. Leading companies continue to focus on developing new and improved molecules with shorter dosing frequency and improved safety and tolerability, reducing the performance gap with injectable medications. For example, metabolization data suggests that new products will have the same efficacy as injectable medication, further reassuring clinicians and embarking on the road to acceptance.

• Expanding the range of treatment indications and clinical use: Oral GLP-1 agonists are being utilized more broadly in a wider range of indications than solely T2D. Trials demonstrating efficacy for weight loss and cardiovascular improvement have extended indications in relation to general obesity and cardiometabolic disease. This range of benefits is now capturing the attention of not only physicians but patients as well and therefore demand for the treatments is increasing at more rapid rates. Also, updated clinical guidelines are now including GLP-1 based therapies in standard disease management recommendations, including evidence of CVD risk reduction that further reinforces the utility of these therapies for long-term market growth.

What are the Significant Developments that are Powering up the Oral GLP-1 Agonists Market today?

• Breakthrough advancements in Gastrointestinal absorption technologies: The oral GLP-1 agonists market is witnessing breakthrough advances in the innovative absorption platforms that can help peptide molecules stay intact through the unrelenting conditions of the gastrointestinal tract. Researchers are designing novel technologies such as permeation enhancers, carrier molecules and pH sensitive coatings that can synergize stability and absorption to quicken drug uptake into the bloodstream. Such breakthrough technologies are helping overcome the long-standing problems of oral peptides and eventually enabling drug makers to come up with highly lucrative oral formulations. The rising convenience of treatment is further spurring popularity among the masses, thus making oral GLP-1 agonists more presentable in competitive positioning against their injectable counterparts.

• Innovations in Multi-Target and Combination Therapies: There is a fast evolving pipeline of combination therapies that simultaneously target multiple pathways within metabolic disease. The market is beginning to bifurcate into those developing dual and triple receptor agonists (GLP-1, GIP, and glucagon) to optimize outcomes and those developing multiple single pathway agonists, which ultimately cannot match the efficacy potential of the multifunctional approach. The development of dual and triple receptor therapies enhances the therapeutic potential and clinical opportunity as well as the competitive landscape.

• Emergence in Preventive and Early-Stage Treatment Markets: Growing enthusiasm among clinicians to focus on disease prevention and early intervention is encouraging the use of oral GLP-1 for early-stage metabolic therapy. Physicians are now starting to use these treatments earlier as a cost-effective, non-invasive approach for managing long-term prognosis by introducing them in cases far earlier than when administration of more aggressive treatments is required. Their relative simplicity of use and administration is attracting a greater number of patients requiring minimal intervention and broadening the current treatment market. Increased demand from new patient segments will therefore lead to higher prescription numbers.

• Building Commercial Strength and Market Access Initiatives: Companies are focused on building commercial strength by expanding globally, improving product positioning and Pricing, designing more sophisticated distribution strategies, and creating new routes to market. Product availability is being expanded in primary emerging markets while maintaining a solid presence in some developed countries. First mover advantage, formulary access negotiations, strategic cooperation, co-marketing agreements, and investments into large-scale manufacturing plants to cater to the demand are helping companies respond to the expectations of a rapidly growing market. Meanwhile, an increasingly greater inclination of healthcare providers and payers to consider oral GLP-1 agonists as a positive clinical solution to treat their patients is, first and foremost improving reimbursement coverage scenarios.

Category Wise Insights

By Product

Why Semaglutide Leads the Market?

Semaglutide accounts for the top spot in the oral GLP-1 agonist space, owing to its excellent clinical efficacy in both lowering blood glucose levels and weight reduction, as well as its relatively early entry to the oral formulations market. It is widely prescribed with a high level of confidence by physicians given the evidence that is available in the treatment of T2DM and obesity, along with a strong clinical package and regulatory support. It has the convenience of once-daily oral administration, which is preferred over injectable formulations among patients and physicians, as well as a robust commercial presence and ongoing label expansions.

Tirzepatide looks set to be the fastest growing segment due to its unique dual-action mechanism of action. Utilizing both the GLP-1 and GIP receptors, Tirzepatide can therefore bring greater better metabolic benefits. Dulaglutide and lixisenatide continue to be key molecules in terms of importance for the time being, however, as the pipeline molecules can offer a wide variety of innovative formulations the competition is growing.

By Application

Why Type 2 Diabetes Mellitus Dominates the Market?

Type 2 diabetes mellitus is the dominant segment of the oral GLP-1 agonists market, driven by the worldwide prevalence of the disease and the demand for effective long term glucose management therapies. GLP-1 oral therapies offer an array of benefits including enhanced glucose control, weight management and a lesser hypoglycemic effect. Continued growth is also expected from increasing awareness, earlier onset of diagnosis and adapting treatment methodologies.

Obesity / chronic weight management is the fastest growing segment, driven by the escalation of world obesity and the growing body of evidence for the utility of GLP-1 therapies in weight loss. Cardiovascular risk management also appears to be gaining momentum as these agents are increasingly showing benefit in reducing the risk of major cardiovascular events.

By Route of Administration

Why Injectable / Parenteral Segment Leads the Market?

Generally speaking, injectables/parenterals are the space that has had the strongest hold on the oral GLP-1 agonists market. Thanks to a longstanding success story and the multitude of oral formulations that have been in clinical use for years, this segment of the market has an extensive infrastructure, a firmly established reputation and a notable portfolio that translates into overall efficacy.

In comparison, the oral segment is the fastest growing area and this is due to the rising prevalence of non-invasive therapies coupled with increasing patient compliance and acceptance. Oral drugs avoid the pain and inconvenience caused by injections and thus are very attractive for the treatment of early cancer and chronic conditions. Improving drug delivery methods for oral drugs is likely to enhance this transition.

Report Scope

Regional Analysis

What is driving the dominance of the Asia Pacific in 2025?

Asia Pacific is projected to hold a major position in the oral GLP-1 agonists market owing to the rising prevalence of obesity and diabetes at a fast pace along with an increasing share of healthcare. Metabolic disorders are on the rise in China, India, and Japan due to urbanization and lifestyle booms. With the growing healthcare infrastructure, the region is experiencing a surge in middle class population, high awareness about advanced therapies and new opportunities for investment have boosted market growth. Moreover, the rising number of alliances, partnerships and manufacturing activities of MNCs in the region have bolstered the momentum. Further, improved government initiatives and rising demand for new compounds are contributing toward strengthening the lead.

China Market Trends

China is an important market for oral GLP-1 agonists owing to its significant size of diabetic population and developing focus on breakthrough therapeutic options. Growing awareness about chronic diseases and the desire to have healthcare in the palm has increased the demand for easy and readily available therapies. Favorable policies regarding widening coverage for healthcare and increasing funds for innovation are expected to lead further market development. Moreover, local companies are also focusing on drug development and commercialization strategies by partnering with other key players in order to gain a foothold in the market. Government is also stressing better access to leading therapies to reduce disease burden and improve patient care.

What is the Reason behind the steady Growth in North America?

North America is one of the markets showing steady growth in oral GLP-1 agonists owing to the high prevalence of the disease and early adoption of newer drugs. The developed healthcare infrastructure, reimbursement mechanisms, and high patient awareness there ensure early acceptance of new therapeutics. The growing pipeline of new products and driving presence of clinical research infrastructure are pushing product adoption in the market. Moreover, the ever growing focus on obesity and preventative care is further propelling demand.

What is the Market Size of the U.S.

In the 2016 to 2025 period, the overall market size of the oral GLP-1 agonists market in the US is projected to be valued at USD 43.8 billion in 2025. Market is predicted to grow at a CAGR of 12.17% in the forecast period 2016 to 2025.

U.S. Market Trends

The U.S. Market is driven by a high level of innovation and high clinical adoption of GLP-1 therapies. Further introduction and increasing preference of oral formulations are expected to improve patient adherence and treatment access. The market is also experiencing a significant increase in demand for weight management therapies, translating into an increased market share. Other factors contributing to strong growth in the U.S. Market are strategic collaborations among GCP-1 players, research and academic institutes and healthcare providers to hasten the development of next-generation therapies and reimbursement policies as well as reports of impressive clinical benefits from focusing on value-based care.

What is the Reason behind Europe Implementing Sustainability and Efficiency?

Europe represents a large market for oral GLP-1 agonists because it has well-developed healthcare and chronic disease management systems that aim at optimizing healthcare outcomes. Based on a strong tradition in evidence-based treatments combined with a cost effective healthcare system many age related diseases are coming to market earlier in a chronic disease guideline framework. As a consequence, the prevalence of diseases like diabetes and obesity among an aging population is constantly rising. Regulatory bodies already acknowledged the clinical and scientific implementation of oral GLP-1s, which can be highly beneficial from the integrated healthcare system. Growing awareness for preventive measures and early interventions will further strengthen the market.

Germany Market Trends

Germany is an important contributor to the European market for oral GLP-1 agonists. Due to its focus on innovation and modern healthcare provisioning, Germany's healthcare market is quick to adopt novel therapies and has an efficient reimbursement system in place. The prevalence of diseases related to metabolic syndromes is on the rise, as is demand for increased weight management, both factors which will contribute to the growth of the new therapeutic class within the country, along with collaborative research efforts from contributors such as pharmaceutical companies and research institutes.

What is the Reason why the Middle East & Africa Region is Growing?

The growth of the oral GLP-1 agonist market in the Middle East & Africa region is slow and steady, observing significant growth in prescription patterns owing to growing awareness of chronic and lifestyle diseases coupled with massive development of healthcare facilities and systems. The burden of diabetes is multiplying especially in Gulf countries thereby increasing the footfalls of patients seeking effective treatment options. Other factors contributing towards growth include the modernized healthcare system, expanded access to newer therapies and the presence of private healthcare sectors in the region along with collaborations with global pharmaceutical giants. The market has huge opportunity but is at initial stages of adoption. With increased focus on disease management and preventive healthcare, the market is expected to observe steady growth in the coming years.

Top Players in the Market and Their Offerings

• Novo Nordisk A/S

• Eli Lilly and Company

• Pfizer Inc.

• AstraZeneca plc

• Sanofi S.A.

• Roche Holding AG

• Merck & Co. Inc.

• Boehringer Ingelheim International GmbH

• Johnson & Johnson

• Amgen Inc.

• Structure Therapeutics Inc.

• Viking Therapeutics Inc.

• Altimmune, Inc.

• Zealand Pharma A/S

• Hanmi Pharmaceutical Co. Ltd.

• Others

Key Developments

The market has been widely evolved so that the players in the business have wanted to complete the most management of the activities and to improve its product line.

• In June 2024, Teva Pharmaceutical Industries Ltd. Launched the first generic GLP-1 therapy in the U.S. In the form of an authorized generic of the branded Victoza (liraglutide injection 1.8 mg). The launch of a generic GLP-1 product augments the company's complex generics business (comprising CVS and existing generic GLP-1 products) and offers a more competitively priced GLP-1 treatment to improve access for individuals needing these therapies.

• In March 2024, FDA approval was granted for Wegovy (semaglutide) for the reduction of risk of major adverse cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death) in adults with obesity or overweight and cardiovascular disease. This makes Wegovy the first weight management medicine to gain a cardivascular risk reduction indication, showing significantly better results versus placebo.

This kind of strategic approach is allowing companies to strengthen their competitive position, advance a new range of products, and benefit from the ongoing growth of disposable and minimally invasive surgery worldwide.

The Oral GLP-1 Agonists Market is segmented as follows:

By Product

• Semaglutide

• Tirzepatide

• Dulaglutide

• Liraglutide

• Others

By Application

• Type 2 Diabetes Mellitus

• Obesity / Chronic Weight Management

• Cardiovascular Risk

By Route of Administration

• Injectable / Parenteral

• Oral

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America